CLDI 10-Q: SEC filing
Calidi Biotherapeutics
Filed with the SEC on · accession 0001193125-26-460940
CLDI filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -5.1% by the first close after the filing.
Summary of the filing
Calidi Biotherapeutics filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing various financing activities including registered direct offerings, warrant issuances, and lease terminations.
Key details
How CLDI stock reacted
Close before
$0.66
Nov 12, 2026
First close after
-5.08%
$0.62
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for CLDI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CLDI?
Click hereFrequently asked questions
What did CLDI file with the SEC on Nov 13, 2026?
CLDI filed a 10-Q (SEC filing). Calidi Biotherapeutics filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing various financing activities including registered direct offerings, warrant issuances, and lease terminations.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did CLDI stock react to this filing?
CLDI closed at $0.66 before the filing and $0.62 on Nov 13, 2026 (-5.08%).
Other CLDI SEC filings
Get alerts when CLDI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days